HC Wainwright cut shares of Imago BioSciences (NASDAQ:IMGO – Get Rating) from a buy rating to a neutral rating in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has $36.00 price objective on the stock, up from their previous price objective of $35.00.
IMGO has been the subject of several other research reports. Cowen downgraded shares of Imago BioSciences from an outperform rating to a market perform rating and set a $36.00 price target for the company. in a research report on Monday. Wedbush downgraded shares of Imago BioSciences from an outperform rating to a neutral rating and set a $36.00 price target for the company. in a research report on Monday. Jefferies Financial Group downgraded shares of Imago BioSciences from a buy rating to a hold rating and upped their price target for the company from $35.00 to $36.00 in a research report on Monday. Finally, Cowen downgraded shares of Imago BioSciences to a market perform rating and set a $36.00 price target for the company. in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Imago BioSciences presently has an average rating of Hold and an average target price of $36.00.
Imago BioSciences Stock Performance
Shares of NASDAQ:IMGO opened at $35.64 on Tuesday. The company has a market cap of $1.21 billion, a PE ratio of -19.37 and a beta of 1.94. Imago BioSciences has a 52 week low of $11.56 and a 52 week high of $35.75. The firm has a 50 day simple moving average of $17.66 and a 200 day simple moving average of $16.24.
Institutional Inflows and Outflows
About Imago BioSciences
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.